Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Ado-Trastuzumab Emtansine (Kadcyla™)

Last Updated: 03/28/17

Status: Potential NF2 Clinical Trial


  • Treatment Information
  • Side Effects
  • Additional Information
Other Names T-DM1, trastuzumab emtansine, trastuzumab-DM1,
Trade Name Kadcyla™
Pharmaceutical Company Genentech
Treatment By IV - Injection
Treatment Form Antibody-Drug Conjugate (ADC)
Inhibitor HER2 Human Epidermal Growth Factor Receptor 2

1. Treatment Information

On February 22, 2013, the U.S. Food and Drug Administration approved of Kadcyla for the treatment of people with HER2-positive metastatic breast cancer.

This medication may help NF2 tumors, but it is not in trial because of the severe side effects of Kadcyla are life threatening. But, this medication was developed using a new method of combining chemical compounds. This new method will allow for an entirely new line of treatments that will result in better management of a wide variety of tumour issues.

Not to be confused with Trastuzumab (Herclon™ or Herceptin™).

2. Side Effects

Minimal Side Effects:

  • Fatigue
  • Nausea
  • Musculoskeletal pain
  • Thrombocytopenia (low platelet counts)
  • Headache
  • Increased liver enzyme levels
  • Constipation

Severe Side Effects:

  • Hepatotoxicity (liver damage)
  • Rare cases of liver failure
  • Hepatic encephalopathy
  • Nodular regenerative hyperplasia; heart damage (dysfunction of the left ventricle) and interstitial lung disease
  • Acute interstitial pneumonitis; thrombocytopenia; and peripheral neuropathy

3. More Information

What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021